Novartis Goes First

Novartis' CAR-T cell therapy is now the first of its kind to be approved by the FDA, reports Marketwatch. The pharmaceutical company's Kymriah, the first gene therapy available in the US, will be accessible to young people up to age 25 with a form of acute lymphoblastic leukemia.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

British Nobel laureates and Fields Medal winners warn that a 'hard' Brexit could harm science across the UK, the Guardian reports.

Vox reports on inequities in genetic research and efforts to address them.

The New York Times reports that Arizona State University's Lawrence Krauss is retiring following allegations of sexual misconduct.

In PNAS this week: de novo NUS1 mutations linked to Parkinson's disease risk, candidate hepatocellular carcinoma drivers, and more.